"Ozempic Face" Prevention: A New Risk Model

GLP-1 receptor agonists like semaglutide (sold as Ozempic and Wegovy) can produce significant weight loss, but that loss is not evenly distributed across the body. In some patients, the face loses volume faster and more visibly than other regions, producing a drawn, aged look that media and clinicians have taken to calling "Ozempic face." A new paper published in Aesthetic Plastic Surgery on 8 June 2026 proposes moving from reactive correction to prevention, offering an anatomy-driven risk stratification model and a four-phase algorithm for managing these facial changes before they become severe^[1].

What is "Ozempic face"

The term is informal. It describes the accelerated facial aging some people experience during rapid weight loss on GLP-1 receptor agonists. The changes include deflation of superficial fat compartments in the midface, increased skin laxity, deepening of the nasolabial folds, and hollowing around the temples and cheeks^[2]. A 2025 systematic review of 23 articles found that GLP-1 receptor agonists cause "morphological changes resembling advanced aging" and that online searches for "Ozempic face" correlated with rising searches for "face filler" and "plastic surgeons"^[3].

A separate 2026 analysis of over 820,000 female patients found that those on GLP-1 receptor agonists were more than twice as likely to undergo upper eyelid blepharoplasty (hazard ratio 2.22; 95% CI 1.51-3.26; p < 0.001) compared to controls, and that weight loss alone without GLP-1 therapy did not show the same association^[4]. That finding suggests something beyond simple caloric-deficit weight loss may be at play, though the mechanism is not yet settled.

What the new paper proposes

The paper by Castrellon and colleagues introduces two linked tools. The first is a risk stratification model based on facial anatomy. Rather than treating all patients on GLP-1 drugs as equally likely to develop visible facial aging, the model uses baseline anatomical features to sort patients into risk tiers before significant weight loss occurs^[1].

The second tool is a four-phase prevention algorithm aligned with the stages of weight loss. The idea is that different interventions apply at different points in the weight-loss timeline. Early phases focus on assessment and monitoring; later phases address emerging volume loss with procedures timed to prevent rather than correct advanced changes^[1].

How risk stratification works

The model draws on the anatomy of the facial fat compartments. The face contains both superficial and deep fat pads, and these compartments deflate at different rates and with different visual consequences. The midface superficial compartments appear particularly vulnerable, contributing to contour flattening and more pronounced transitional lines between facial zones^[2]. Patients with less baseline facial volume, thinner skin, or age-related skeletal resorption already underway are categorised as higher risk^[1].

The four-phase algorithm

The prevention algorithm is structured around the progression of GLP-1-mediated weight loss. The authors propose that clinicians assess facial anatomy at baseline (before or at the start of GLP-1 therapy), monitor at defined intervals as weight loss progresses, intervene early with less invasive approaches when initial volume changes appear, and reserve more extensive procedures for patients whose anatomy and rate of loss place them in the highest risk categories^[1].

Why anatomy matters

A separate 2026 paper in Dermatologic Surgery examined the anatomical mechanisms in more detail. Frank and colleagues describe how midface volume loss occurs mainly in superficial fat compartments, and that the combined effect of fat deflation, diminished deep structural support, skeletal resorption, and heightened skin laxity produces the visible aging pattern^[2]. They advocate for early biostimulation (collagen-stimulating agents) combined with selective hyaluronic acid-based structural restoration as a treatment strategy.

This anatomical perspective is what distinguishes the Castrellon model from earlier approaches. Most published guidance on "Ozempic face" has focused on correcting changes after they are already advanced. The new framework attempts to identify who is most vulnerable before the changes become pronounced, and to match prevention intensity to individual risk^[1].

Limitations and what comes next

The authors describe their model as hypothesis-generating. It has not been validated in a prospective clinical trial. The risk tiers and the four-phase algorithm are based on anatomical reasoning and clinical observation, not on outcome data showing that stratified patients who received early intervention had better long-term results than those who did not^[1].

There is also no consensus on whether GLP-1 receptor agonists produce facial volume loss through a mechanism distinct from ordinary caloric-deficit weight loss, or whether the effect is simply faster and more visible because the drugs produce larger and more rapid total weight reduction. The question applies equally to other GLP-1 drugs, including dual-agonist tirzepatide (Mounjaro, Zepbound), which can produce comparable or greater weight loss. The blepharoplasty data suggesting a GLP-1-specific effect beyond weight loss alone is observational and cannot establish causation^[4].

Future work would need to follow patients prospectively through GLP-1 treatment, apply the risk model at baseline, track facial volume changes with imaging, and compare outcomes between those who received early intervention and those who did not. Until that validation exists, the model remains a proposed framework rather than an established clinical protocol.

This article is for informational purposes only. It does not constitute medical advice. If you are experiencing facial changes related to weight loss or medication, consult a qualified healthcare provider.